Sander Dale A. 4

What Happened
Dale A. Sander, Humacyte’s Chief Financial Officer and Chief Corporate Development Officer, disposed of 45,887 shares of Humacyte common stock on 2026-05-18 at $0.90 per share, generating proceeds of $41,147. This was a sale (not a purchase) and reflects a routine sell-to-cover transaction related to vested restricted stock units, not a discretionary trade for investment purposes.

Key Details

• Transaction date and price: 2026-05-18 at $0.90 per share; total proceeds $41,147.
• Transaction type/code: Sale (S); footnote indicates tax withholding (F) via automated "sell-to-cover."
• Footnote summary: Shares were sold to satisfy statutory tax withholding on vested RSUs under a plan intended to meet Rule 10b5-1(c) affirmative defense conditions; the sale was mandated by issuer practice and not a discretionary sale by the reporting person.
• Filing: Form 4 filed 2026-05-20 for the 2026-05-18 transaction (appears timely).
• Shares owned after transaction: Not specified in the provided filing summary.

Context
Sell-to-cover transactions are common when restricted stock units vest and generally reflect tax withholding needs rather than a signal about the executive’s view on the company. Purchases typically carry more informational weight for investors; this filing documents a routine withholding sale.